Delee is a medical device company based in Monterrey, Mexico, that develops a blood-testing device for the early diagnosis of cancer and ongoing treatment monitoring. The company's core innovation is centered on the isolation and analysis of circulating tumor cells (CTCs), allowing clinicians to detect cancer at an early stage and track treatment effectiveness through non-invasive blood samples. Delee operates in the healthcare diagnostics space, with a particular focus on making advanced cancer diagnostics more accessible in Latin America and beyond.
The technology that enabled Delee
Delee's main technology leverages advancements in microfluidics and cellular analysis to isolate and analyze rare circulating tumor cells directly from a patient's blood. Identifying these CTCs offers a minimally invasive alternative to traditional tissue biopsies, providing timely information about cancer presence and progression. This approach helps clinicians make more informed decisions about diagnosis, prognosis, and treatment strategies, supporting the broader trend toward liquid biopsy-based cancer management.
Who uses Delee's platform?
Delee primarily serves oncologists, cancer centers, and diagnostic laboratories seeking more efficient and patient-friendly methods for cancer detection and monitoring. Their solution is especially relevant for healthcare providers in regions where access to cutting-edge diagnostics is limited, such as Mexico and Latin America. The technology is designed to support both early-stage cancer detection and ongoing monitoring of existing cancer patients.
Who are Delee's competitors?
Delee operates within the circulating tumor cell (CTC) detection and liquid biopsy market. Notable competitors in this space include:
- CellSearch: The only FDA-approved system for CTC detection, primarily used for breast, colorectal, and prostate cancer diagnostics. CellSearch is an established incumbent with a robust clinical track record.
- RareCyte: Offers circulating tumor cell analysis and imaging solutions for research and clinical applications, focusing on high-sensitivity detection of rare cells.
- ctDNA Testing Providers: Beyond CTCs, companies offering circulating tumor DNA (ctDNA) analysis—such as Guardant Health and Foundation Medicine—also represent competition by providing alternative liquid biopsy methods for cancer detection and monitoring.
While Delee focuses on CTC analysis, its differentiation lies in bringing this technology to under-served markets and potentially offering a cost-effective, user-friendly platform tailored for broader adoption.
Use PromptLoop to Uncover Company Data
Looking for more company insights like this? PromptLoop helps you go deeper, providing unique data points and analysis on companies like Delee and many others. Automate your research and find the information that matters most. Discover how PromptLoop can accelerate your market intelligence. Get A Free Demo to learn more.